PEPTALK: Advancing CNS Biotherapeutics and Crossing the Blood-Brain Barrier Presentation
AACR 2019 Meeting: Altered myeloid & lymphoid composition of tumor microenvironment following anti-SEMA4D and immunotherapies
AACR 2019 Meeting: Integrated biomarker trials of VX15/2503 (pepinemab) in combination with checkpoint inhibitors in window of opportunity studies in solid tumors
AACR 2019 Meeting: Interim results from CLASSICAL-Lung, a phase 1b/2 Study of VX15/2503 (pepinemab) in combination with avelumab in advanced NSCLC
Poster Presented on April 29, 2019 at AACR-AHNS Head and Neck Cancer Conference: “Integrated biomarker trials to evaluate myeloid and lymphoid composition of HNSCC and solid tumors treated with pepinemab and combinations with checkpoint inhibitors”
ASCO 2019 TIP abstract 4400-18.pdf
ASCO Annual Meeting Abstract: Preliminary Results From CLASSICAL-Lung, a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
ASCO Annual Meeting Poster: Preliminary Results From CLASSICAL-Lung, a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
CLASSICAL_ASCO 2019 poster_FINAL.pdf
ASCO Annual Meeting Poster: Pilot Integrated Biomarker Study of VX15/2503 in Combination with Ipilimumab and/or Nivolumab in Patients with Resectable Metastatic Melanoma